ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

Medenica Granted Extension Of Privileges At Hilton Head Hospital

November 26, 1993

Cancer Groups Endorse Pazdur For FDA Commissioner.

January 19, 2001

In Brief: 163 PIs Hold Both Contracts, Grants; Hopkins Scientists Questions Retrospective Diet Studies

August 27, 1976

Rosenberg’s Adoptive Immunotherapy Update

December 6, 1985

In Brief: Glick, Armitage Lead ASCO; NCAB Approves Resolution Calling For Higher NIH Budget

June 2, 1995

CAP Issues Active Surveillance Guidance For Prostate Cancer

September 5, 2014